Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;147(2):600-612.
doi: 10.1016/j.jaci.2020.04.031. Epub 2020 May 1.

Activation of the 15-lipoxygenase pathway in aspirin-exacerbated respiratory disease

Affiliations

Activation of the 15-lipoxygenase pathway in aspirin-exacerbated respiratory disease

Whitney W Stevens et al. J Allergy Clin Immunol. 2021 Feb.

Abstract

Background: Aspirin-exacerbated respiratory disease (AERD) is characterized by asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and an intolerance of medications that inhibit cyclooxygenase-1. Patients with AERD have more severe upper and lower respiratory tract disease than do aspirin-tolerant patients with CRSwNP. A dysregulation in arachidonic acid metabolism is thought to contribute to the enhanced sinonasal inflammation in AERD.

Objective: Our aim was to utilize an unbiased approach investigating arachidonic acid metabolic pathways in AERD.

Methods: Single-cell RNA sequencing (10× Genomics, Pleasanton, Calif) was utilized to compare the transcriptional profile of nasal polyp (NP) cells from patients with AERD and patients with CRSwNP and map differences in the expression of select genes among identified cell types. Findings were confirmed by traditional real-time PCR. Lipid mediators in sinonasal tissue were measured by mass spectrometry. Localization of various proteins within NPs was assessed by immunofluorescence.

Results: The gene encoding for 15-lipooxygenase (15-LO), ALOX15, was significantly elevated in NPs of patients with AERD compared to NPs of patients with CRSwNP (P < .05) or controls (P < .001). ALOX15 was predominantly expressed by epithelial cells. Expression levels significantly correlated with radiographic sinus disease severity (r = 0.56; P < .001) and were associated with asthma. The level of 15-oxo-eicosatetraenoic acid (15-Oxo-ETE), a downstream product of 15-LO, was significantly elevated in NPs from patients with CRSwNP (27.93 pg/mg of tissue) and NPs from patients with AERD (61.03 pg/mg of tissue) compared to inferior turbinate tissue from controls (7.17 pg/mg of tissue [P < .001]). Hydroxyprostaglandin dehydrogenase, an enzyme required for 15-Oxo-ETE synthesis, was predominantly expressed in mast cells and localized near 15-LO+ epithelium in NPs from patients with AERD.

Conclusions: Epithelial and mast cell interactions, leading to the synthesis of 15-Oxo-ETE, may contribute to the dysregulation of arachidonic acid metabolism via the 15-LO pathway and to the enhanced sinonasal disease severity observed in AERD.

Keywords: 15-lipoxygenase; 15-oxo-eicosatetraenoic acid; AERD; ALOX15; CRSwNP; Chronic sinusitis; aspirin-exacerbated respiratory disease; hydroxyprostaglandin dehydrogenase; nasal polyps.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest:

RC, DC, KH, JH, JN, CP, AS, SS, LS, DW, and KW reports no conflicts of interest. WS served on an advisory board for GlaxoSmithKline. AK reports personal fees from Astellas Pharmaceuticals. BT reports personal fees from Sanofi Regeneron/Genzyme, and OptiNose. AP reports personal fees from Sanofi Regeneron and personal fees and grants from AstraZeneca. LG reports personal fees from Astellas Pharmaceuticals. RK reports personal fees from Sanofi, Novartis, Lyra Pharmaceutical, and Neurent. RS reports personal fees from Intersect ENT, Merck, GlaxoSmithKline, Sanofi, AstraZeneca/Medimmune, Genentech, Actobio Therapeutics, Lyra Therapeutics, Astellas Pharma Inc., and Otsuka Inc. RS also has Siglec-8 and Siglec-8 ligand related patents licensed to Allakos Inc.

Figures

Figure 1.
Figure 1.. scRNA-seq analysis of cells from nasal polyps from CRSwNP and AERD patients.
scRNA-seq analysis of combined nasal polyp cells from CRSwNP and AERD patients identified 26 cell clusters (A). Clusters were annotated based upon expression of canonical genes: KRT5 (basal epithelial cells), KRT8 (apical epithelial cells), LTF (glandular epithelial cells), FOXJ1 (ciliated epithelial cells), COL1A2 (fibroblasts), ACKR1 (endothelial cells), CD79A (B cells), TRBC2 (T cells), HLA-DRA (myeloid), and TPSAB1 (mast cells) (B). Clusters containing the same cell types were combined together resulting in 10 unique clusters (C). Scaled expression of key genes involved in arachidonic acid metabolism and signaling via the 5-LO (D) and COX (E) pathways.
Figure 2.
Figure 2.. 15-oxo-ETE, but not 5-oxo-ETE, was elevated in nasal polyps.
Levels of 5-oxo-ETE and 15-oxo-ETE were measured by HPLC-MS/MS in sinonasal tissues. Representative traces from a NP sample illustrating the relative abundance and mass per charge (m/z) ratios of 5-oxo-ETE and 15-oxo-ETE (A-C). Levels of 5-oxo-ETE (D) and 15-oxo-ETE (E) were quantified from sinonasal tissue samples from healthy control, CRSsNP, CRSwNP, AERD patients. 15-oxo-ETE was significantly elevated in NP tissues from both CRSwNP and AERD patients. Dot plots illustrate individual data points with solid lines representing the mean ± SEM. Statistical significance (p<0.05) was determined by Kruskal-Wallis test with post-hoc analysis using the Dunn’s test for multiple comparison; **p<0.01 and ***p<0.001.
Figure 3.
Figure 3.. ALOX15 was elevated in ciliated and apical epithelial cells and correlated with eosinophils in AERD and CRSwNP nasal polyps.
Violin plots of normalized ALOX15 gene expression in all NP cells (A), in all epithelial cells (apical, basal, ciliated, and glandular subsets) (B), and in individual cell clusters (C) from AERD and CRSwNP patients. ALOX15 expression was highest in ciliated and apical epithelial cells and, in these clusters, was elevated in AERD compared CRSwNP NP (C). ALOX15 expression was measured in separate sinonasal tissue samples by qRT-PCR, and was highest in NP from AERD patients (D). Increased expression of ALOX15 significantly correlated with expression of CLC (E) and with protein levels of Eosinophilic Cationic Protein (ECP) (F) among matched sinonasal tissues. Dot plots illustrate individual data points with solid lines representing the mean ± SEM. Statistical significance (p<0.05) was determined by Wilcoxon rank sum (A-C), by Kruskal-Wallis test with post-hoc analysis using the Dunn’s test for multiple comparison (D), or Spearman’s rank correlation (E-F); *p<0.05, ***p<0.001, ****p<0.0001.
Figure 4.
Figure 4.. 15-HETE was not elevated in CRSwNP or AERD nasal polyps.
15-HETE was detected in sinonasal tissues by HPLC-MS/MS. Representative plots from a NP sample illustrating the peak and m/z of 15-HETE (A-B). Quantification of 15-HETE in sinonasal samples found no significant difference in levels of 15-HETE among the patient groups. (C). Statistical significance (p<0.05) was determined by Kruskal-Wallis test with post-hoc analysis using the Dunn’s test for multiple comparison. Dot plots illustrate individual data points with solid lines representing the mean ± SEM.
Figure 5.
Figure 5.. HPGD was predominantly expressed by mast cells in AERD and CRSwNP nasal polyps.
HPGD gene expression level superimposed on tSNE of NP cells from AERD and CRSwNP patients (A) with scaled expression levels showing HPGD highest in mast cells (B). HPGD expression was measured in separate sinonasal tissue samples by qRT-PCR, and was elevated in NP from both CRSwNP and AERD patients compared to control (C). HPGD expression correlated with expression of TPSB2 in matched sinonasal tissue samples (D). NP were stained by immunofluorescence using no primary control (E) or with HPGD (green) and tryptase (red) in CRSwNP (F) and AERD (G) NP. The majority of HPGD+ cells detected also stained positive for the mast cell marker tryptase. Dot plots illustrate individual data points with solid lines representing the mean ± SEM. Statistical significance (p<0.05) was determined by Kruskal-Wallis test with post-hoc analysis using the Dunn’s test for multiple comparison (C) or Spearman’s rank correlation (D); *p<0.05 and **p<0.01.
Figure 6.
Figure 6.. ALOX15-expressing epithelial cells and HPGD-expressing mast cells co-localized within AERD and CRSwNP nasal polyps.
Gene expression of HPGD and ALOX15 across patients is positively correlated in CRSwNP and AERD NP as measured by scRNA-seq (A) or by qRT-PCR (B) in matched sinonasal tissue samples (B). NP were stained by immunofluorescence using no primary control (C) or with HPGD (green) and 15-LO (red) in CRSwNP (F) and AERD (G) NP. HPGD+ mast cells were localized in close proximity to 15-LO+ epithelial cells in NP. Statistical significance (p<0.05) was determined by Spearman’s rank correlation (A-B).
Figure 7.
Figure 7.. ALOX15 gene expression correlated with sinonasal disease severity.
ALOX15 gene expression was measured by qRT-PCR in control UT, CRSsNP UT, CRSwNP NP, and AERD NP and analyzed according to the patient’s asthma status (A), degree of asthma severity (B), Lund-Mackay score (C), and number of sinus surgeries (D). Dot plots illustrate individual data points with solid lines representing the mean ± SEM. Statistical significance (p<0.05) was determined by Kruskal-Wallis test with post-hoc analysis using the Dunn’s test for multiple comparison (A, B) or Spearman’s rank correlation (C); *p<0.05, **p<0.01, and ***p<0.001.

Comment in

Similar articles

Cited by

References

    1. Bhattacharyya N, Villeneuve S, Joish VN, Amand C, Mannent L, Amin N, et al. Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope 2019. - PMC - PubMed
    1. Promsopa C, Kansara S, Citardi MJ, Fakhri S, Porter P, Luong A. Prevalence of confirmed asthma varies in chronic rhinosinusitis subtypes. Int Forum Allergy Rhinol 2016; 6:373–7. - PMC - PubMed
    1. Stevens WW, Peters AT, Hirsch AG, Nordberg CM, Schwartz BS, Mercer DG, et al. Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease. J Allergy Clin Immunol Pract 2017; 5:1061–70 e3. - PMC - PubMed
    1. Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol 2015; 135:676–81 e1. - PubMed
    1. Batra PS, Tong L, Citardi MJ. Analysis of comorbidities and objective parameters in refractory chronic rhinosinusitis. Laryngoscope 2013; 123 Suppl 7:S1–11. - PubMed

Publication types

Substances